Results 111 to 120 of about 728 (161)

Favorable cardiac remodeling in response to treatment in obstructive hypertrophic cardiomyopathy: a current appraisal. [PDF]

Future Cardiol
Keen S, Desai MY.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy

New England Journal of Medicine
BACKGROUND Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy.
Ahmad Masri, Roberto Barriales Villa, Perry M Elliott   +2 more
exaly   +3 more sources

Aficamten in the treatment of obstructive hypertrophic cardiomyopathy.

Future Cardiology
Aficamten is a novel cardiac myosin inhibitor that has completed a Phase III trial for the treatment of obstructive hypertrophic cardiomyopathy (HCM). Aficamten was developed to optimize pharmacokinetic properties and clinical tolerability relative to ...
Danish Saleh, Maeve Eskandari, L. Choudhury   +2 more
semanticscholar   +2 more sources

Aficamten for Obstructive Hypertrophic Cardiomyopathy

New England Journal of Medicine
Jorge, Pedreira-Bouzas, Álvaro, Pousada-Fonseca, Dolores, Fraga   +2 more
exaly   +4 more sources

Aficamten reduces symptoms in obstructive hypertrophic cardiomyopathy

Nature Reviews Cardiology
exaly   +3 more sources

Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy

American Journal of Cardiovascular Drugs, 2023
Aficamten is a novel cardiac myosin inhibitor that has demonstrated its ability to safely lower left ventricular outflow tract (LVOT) gradients and improve heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM). Based on the REDWOOD-HCM open label extension (OLE) study, participants receiving aficamten had significantly ...
Sneha Annie Sebastian, Inderbir Padda, Eric J. Lehr, Gurpreet Johal   +3 more
openaire   +2 more sources

Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy

Cardiology in Review, 2023
Hypertrophic cardiomyopathy is an under-recognized disease with a genetic component that results in abnormal and often asymmetric thickening of the left ventricle in addition to decreased compliance and progressive fibrosis of the myocardium. It further poses significant complications related to dynamic left ventricular outflow obstruction over time in
Jay, Patel, Andy, Wang, Sihari S, Naidu, William H, Frishman, Wilbert S, Aronow   +4 more
openaire   +2 more sources

Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM.

Journal of the American College of Cardiology
BACKGROUND Beta-blockers have formed the mainstay of first-line therapy for symptomatic obstructive hypertrophic cardiomyopathy (HCM) for decades. Aficamten, compared with placebo, lowered left ventricular outflow tract gradients (LVOT-G), improved ...
S. M. Hegde, Xiaowen Wang, P. García-Pavía, Stoyan Getchevski, Ahmad Masri, B. Merkely, M. Nassif, M. L. Peña-Peña, R. Barriales-Villa, Ozlem Bilen, Melissa Burroughs, B. Claggett, J. Costabel, Edileide de Barros Correia, A. Dybro, Perry Elliott, N. Lakdawala, Amy Mann, M. Maron, Ajith Nair, S. Poulsen, P. Reant, P. Schulze, Andrew Wang, R. Sohn, I. Berhane, S. Heitner, D. Jacoby, S. Kupfer, F. Malik, A. Wohltman, M. Fifer, Scott D. Solomon   +32 more
semanticscholar   +1 more source

Aficamten in non‐obstructive hypertrophic cardiomyopathy: Unlocking new horizons?

European Journal of Heart Failure
N ...
Rossi, Maddalena, Fabris, Enrico, Sinagra, Gianfranco   +2 more
openaire   +3 more sources